LongGame, a $40 million venture capital fund led by crypto investor Will Harbone, aims to advance longevity biotechnology by investing in innovative fields like stem cell research, gene editing, and senolytics. The fund targets early-stage biotech startups and plans to integrate decentralized science (DeSci) tools like DAOs to streamline drug discovery. With a leadership team including COO Chloe Northcott and Special Advisor Sebastian A. Brunemeier, LongGame seeks to democratize access to life-extending therapies and extend healthy human lifespans by 30 years. Harbone envisions leveraging blockchain innovations to address funding gaps in longevity research and disrupt global industries. This initiative aligns with a trend of crypto leaders entering the longevity space, with Coinbase CEO Brian Armstrong co-founding a biotech firm last year. LongGame's mission is to fund therapies that tackle the root causes of aging and make life-extending treatments accessible to the masses. Read more AI-generated news on: https://app.chaingpt.org/news